CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities:
Net income	$ 60,750	$ 130,911
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,228	14,276
Non-cash compensation	12,495	13,463
Amortization and impairment of operating lease right of use assets	22,463	19,702
Loss on disposal of property and equipment	531	8
Gain on equity method investments	0	(31,092)
Deferred income taxes	6,003	22,716
Equity in loss (earnings) from equity method investments	744	(2,488)
Amortization of deferred debt issuance costs/debt discount	495	432
Return on equity method investments	2,428	2,683
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable	(21,344)	(22,787)
Other current assets	(4,468)	3,560
Other assets	220	(52)
Accounts payable	4,498	(6,530)
Accrued expenses	29,529	(1,627)
Other long-term obligations	(223)	(1,736)
Operating lease liabilities	(20,657)	(17,955)
Operating lease right of use assets	(1,662)	(1,524)
Net cash provided by operating activities	106,030	121,960
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets	28	25
Proceeds from the sale of property and equipment	37	42
Purchases of property and equipment	(2,782)	(2,943)
Investments in technology assets	(559)	0
Other investments	(15,000)	0
Acquisitions of businesses, net of cash acquired	(73,311)	(2,503)
Net cash used in investing activities	(91,587)	(5,379)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options	772	623
Proceeds from issuance of stock to employee stock purchase plan	1,891	1,961
Shares withheld to pay taxes on non-cash compensation	(4,762)	(6,944)
Noncontrolling interest contributions	952	0
Noncontrolling interest distributions	(975)	(794)
Proceeds from borrowings under revolving line of credit	298,500	389,200
Repayments of borrowings under revolving line of credit	(283,500)	(410,200)
Principal payments of long-term obligations	(6,975)	(5,392)
Purchase of company stock	(17,351)	(74,074)
Provider relief fund advance	0	(1,672)
Net cash used in financing activities	(11,448)	(107,292)
Net increase in cash, cash equivalents and restricted cash	2,995	9,289
Cash, cash equivalents and restricted cash at beginning of period	45,769	83,357
Cash, cash equivalents and restricted cash at end of period	48,764	92,646
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	4,489	1,914
Cash paid for income taxes, net of refunds received	22,977	8,667
Cash paid for operating lease liabilities	22,319	19,479
Cash paid for finance lease liabilities	735	1,017
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	26,590	20,689
Right of use assets obtained in exchange for finance lease liabilities	1,316	527
Reductions to right of use assets resulting from reductions to operating lease liabilities	2,763	904
Accrued contingent consideration	19,195	0
Noncontrolling interest contribution	$ 8,900	$ 0